9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      COPD, bone metabolism, and osteoporosis.

      Chest
      Adrenal Cortex Hormones, adverse effects, pharmacology, therapeutic use, Bone Density, drug effects, Bone Density Conservation Agents, administration & dosage, Bone and Bones, metabolism, Calcium, Dietary Supplements, Fractures, Bone, epidemiology, Humans, Osteoporosis, prevention & control, Prevalence, Pulmonary Disease, Chronic Obstructive, complications, drug therapy, Risk Factors, Vitamin D, Vitamin D Deficiency

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          COPD and osteoporosis are strongly associated because of common risk factors such as age, smoking, and inactivity. In addition, COPD-related systemic inflammation, vitamin D deficiency, and the use of systemic corticosteroids enhance ongoing bone destruction. Osteoporosis, in turn, may cause fragility fractures, which further impair mobility and increase morbidity and mortality. Vertebral compression fractures and rib cage fractures in patients with COPD may also reduce pulmonary function or enhance exacerbations. Early prevention and treatment of osteoporosis in COPD is, therefore, important and should be based on integrated risk assessment tools such as FRAX, which take bone mineral density, history of fragility fractures, and population-specific clinical factors into account. As long as intervention studies focusing on the bone in COPD are lacking, a more rigorous application of existing treatment guidelines of osteoporosis in general is mandatory.

          Related collections

          Author and article information

          Comments

          Comment on this article